Sesen Bio, Inc.
(NASDAQ : EBIO)

( )
EBIO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.24%343.281.2%$589.37m
GILDGilead Sciences, Inc.
1.33%73.320.9%$534.10m
CELGCelgene Corporation
0.35%91.201.2%$502.04m
AMGNAmgen Inc.
-0.13%197.311.2%$470.98m
ILMNIllumina, Inc.
1.67%331.443.5%$390.25m
REGNRegeneron Pharmaceuticals, Inc.
1.00%378.562.6%$309.76m
VRTXVertex Pharmaceuticals Incorporated
0.65%176.861.9%$202.70m
ALXNAlexion Pharmaceuticals, Inc.
0.71%116.992.0%$186.49m
AAgilent Technologies, Inc.
0.75%64.951.5%$163.20m
SRPTSarepta Therapeutics, Inc.
1.18%129.1416.6%$139.77m
NKTRNektar Therapeutics
2.24%61.965.6%$128.47m
EXASExact Sciences Corporation
1.71%50.0525.3%$122.85m
BLUEBluebird Bio, Inc.
0.06%158.8014.6%$120.19m
BMRNBioMarin Pharmaceutical Inc.
0.72%99.744.4%$119.07m
INCYIncyte Corporation
0.83%69.622.5%$116.18m

Company Profile

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.